A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.

Int J Chron Obstruct Pulmon Dis · 2015 · PMC4603715 · PMID 26504378

Europe PMC DOI

hedged sentence

0.5500

closest p · 11.0× alpha

0.5500

boldest claim

The sentences

did not reach statistical significanceP =0.55not close (p > 0.1)

While the rate of severe exacerbation PPPM decreased to a greater extent in the roflumilast group, this difference did not reach statistical significance ( Figure 3B ; P =0.55).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.